These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12484033)

  • 1. [Pharmacokinetic study of CPT-11, SN-38 and SN-38 glucuronide in the ascites, plasma and bile after intraperitoneal administration of CPT-11].
    Natsui S; Maruyama M; Ochiai T; Hasegawa K; Takashima I; Nagahama T; Ebuchi M
    Gan To Kagaku Ryoho; 2002 Nov; 29(12):2188-90. PubMed ID: 12484033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetic study of the intraperitoneal administration of CPT-11 for patients with peritoneal seedings of gastric and colonic cancers].
    Maruyama M; Toukairin Y; Baba H; Kure N; Nagahama T; Ebuchi M
    Gan To Kagaku Ryoho; 2001 Oct; 28(11):1505-7. PubMed ID: 11707965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experimental study on CPT-11 intraperitoneal chemotherapy--metabolism of CPT-11 in malignant ascites].
    Maruyama M; Toukairin Y; Baba H; Yoshida T; Kure N; Nagahama T; Ebuchi M
    Gan To Kagaku Ryoho; 2000 Oct; 27(12):1858-60. PubMed ID: 11086430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Liver concentration of CPT-11, SN-38 and SN-38 GLU in intraperitoneal and intravenous administration of CPT-11].
    Maruyama M; Nagahama T; Yuasa Y
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1967-9. PubMed ID: 10560438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration.
    Ahn BJ; Choi MK; Park YS; Lee J; Park SH; Park JO; Lim HY; Kang WK; Ko JW; Yim DS
    Eur J Clin Pharmacol; 2010 Dec; 66(12):1235-45. PubMed ID: 20827550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intraperitoneal administration of CPT-11 in rats--experimental study for pharmacokinetics].
    Nagahama T; Maruyama M; Goseki N
    Gan To Kagaku Ryoho; 2000 Oct; 27(12):1866-9. PubMed ID: 11086432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
    Slatter JG; Schaaf LJ; Sams JP; Feenstra KL; Johnson MG; Bombardt PA; Cathcart KS; Verburg MT; Pearson LK; Compton LD; Miller LL; Baker DS; Pesheck CV; Lord RS
    Drug Metab Dispos; 2000 Apr; 28(4):423-33. PubMed ID: 10725311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic assessment of irinotecan, SN-38, and SN-38-glucuronide: a substudy of the FIRIS study.
    Satoh T; Yasui H; Muro K; Komatsu Y; Sameshima S; Yamaguchi K; Sugihara K
    Anticancer Res; 2013 Sep; 33(9):3845-53. PubMed ID: 24023318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biliary excretion of irinotecan and its metabolites.
    Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
    J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic study of two infusion schedules of irinotecan combined with cisplatin in patients with advanced gastric cancer.
    Fujitani K; Tsujinaka T; Hirao M
    Oncology; 2003; 64(2):111-5. PubMed ID: 12566907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38.
    Lin LC; Wang MN; Tsai TH
    Chem Biol Interact; 2008 Aug; 174(3):177-82. PubMed ID: 18579105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine.
    Lokiec F; Canal P; Gay C; Chatelut E; Armand JP; Roché H; Bugat R; Gonçalvès E; Mathieu-Boué A
    Cancer Chemother Pharmacol; 1995; 36(1):79-82. PubMed ID: 7720181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
    Innocenti F; Kroetz DL; Schuetz E; Dolan ME; Ramírez J; Relling M; Chen P; Das S; Rosner GL; Ratain MJ
    J Clin Oncol; 2009 Jun; 27(16):2604-14. PubMed ID: 19349540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of intraperitoneal irinotecan in a pig model.
    Turcotte S; Sideris L; Younan R; Drolet P; Dubé P
    J Surg Oncol; 2010 Jun; 101(7):637-42. PubMed ID: 20461774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats.
    Machida Y; Onishi H; Kurita A; Hata H; Morikawa A; Machida Y
    J Control Release; 2000 May; 66(2-3):159-75. PubMed ID: 10742577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonlinear pharmacokinetics of CPT-11 in rats.
    Kaneda N; Yokokura T
    Cancer Res; 1990 Mar; 50(6):1721-5. PubMed ID: 2306726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic characteristics of the novel anticancer agent CPT-11 and its active metabolite in plasma and lung lymph fluid following intravenous administration to sheep.
    Koizumi T; Kubo K; Hanaoka M; Miyahara T; Kaneki T; Yamamoto H; Ge RL; Fujimoto K; Kobayashi T; Sekiguchi M
    Arzneimittelforschung; 1998 Nov; 48(11):1097-100. PubMed ID: 9850432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
    Itoh T; Itagaki S; Sasaki K; Hirano T; Takemoto I; Iseki K
    J Pharm Pharmacol; 2004 Jun; 56(6):809-12. PubMed ID: 15231047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe CPT-11-induced diarrhea in presence of FK-506 following liver transplantation for hepatocellular carcinoma.
    Gornet JM; Lokiec F; Duclos-Vallee JC; Azoulay D; Goldwasser F
    Anticancer Res; 2001; 21(6A):4203-6. PubMed ID: 11911319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
    Allegrini G; Di Paolo A; Cerri E; Cupini S; Amatori F; Masi G; Danesi R; Marcucci L; Bocci G; Del Tacca M; Falcone A
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):585-93. PubMed ID: 16680463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.